Key result
Extracorporeal shock wave therapy significantly increased LVEF at rest from 32.2±6.0% to 37.7±9.5% (P=0.03) at 6 months in patients with ischemic heart failure.
Why the study?
Does extracorporeal shock wave therapy improve symptoms, functional capacity, and left ventricular function in patients with ischemic heart failure?
Population
24 patients with ischemic heart failure and left ventricular ejection fraction (LVEF) <40%
Design
Case_series
Follow-up
6 months
Authors
Loading...
Should not yet change ischemic HF practice; hypothesis-generating case report data require randomized confirmation.
Does extracorporeal shock wave therapy improve symptoms, functional capacity, and left ventricular function in patients with ischemic heart failure?
p-value: p=0.03
Extracorporeal shock wave therapy may provide significant clinical and functional improvements in patients with ischemic heart failure, warranting further investigation in controlled trials.
Vasyuk et al. (2010) studied Ischemic heart failure (n=24). Extracorporeal shock wave therapy (ESWT) was evaluated on Left ventricular ejection fraction (LVEF) at rest (p=0.03). Extracorporeal shock wave therapy significantly increased LVEF at rest from 32.2±6.0% to 37.7±9.5% (P=0.03) at 6 months in patients with ischemic heart failure.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: